Our initial target market segment in Dermatology is Onychomycosis.
Onychomycosis had an estimated global market size in 2018 of $4.3B with CAGR of 6.9% (25). This growth is fueled by an increase in the population of diabetic and geriatric patients, increasing per capital healthcare spending and consumers’ disposition toward maintaining aesthetically attractive nails. Despite many options available for treatment, the success rate of drugs for onychomycosis treatment is only 40-50% (38).
Onychomycosis can lead to serious complications in diabetic or immunocompromised patients (39). The low success rate may result from lengthy treatment periods, sometimes up to 12 months. Relapse and reinfection rates are >22.5% (40).
As a potent anti-microbial (4-8), NO is a promising alternative solution to infections like onychomycosis. In addition, NO also plays an important role in host defense by its immunoregulatory effects facilitating fungal clearance.
With an already active presence in podiatry via the IonoPulse™ program, onychomycosis is Origin’s continued demonstration of the expanded efficacy of IonoJet™ technology. By utilizing NO’s anti-microbial properties, supported by Origin’s planned collaborative academic anti-microbial research studies, this is a logical entry into the dermatology market.